We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $9.59B
1-Year Est. Return 113.36%
This Fund
S&P 500
This Quarter Est. Return
+6.55%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$8.48B
AUM Growth
+$646M
Cap. Flow
-$743M
Cap. Flow %
-8.77%
Top 10 Hldgs %
50.85%
Holding
160
New
9
Increased
15
Reduced
10
Closed
78

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$83.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$82.1M
3
PFE icon
Pfizer
PFE
+$80.9M
4
GMAB icon
Genmab
GMAB
+$73.8M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$59.1M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$76.2M
2
RVMD icon
Revolution Medicines
RVMD
+$60.3M
3
PHR icon
Phreesia
PHR
+$33.8M
4
VTR icon
Ventas
VTR
+$27.4M
5
SYRE icon
Spyre Therapeutics
SYRE
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 84.65%
2 Miscellaneous 15.35%
3 Consumer Discretionary 0%
4 Consumer Staples 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
26
Dianthus Therapeutics
DNTH
$6.24B
$85.6M 1.01%
+1,019,813
New +$59.1M
PFE icon
27
Pfizer
PFE
$160B
$85.4M 1.01%
+3,040,000
New +$80.9M
NBIX icon
28
Neurocrine Biosciences
NBIX
$15.8B
$80.4M 0.95%
610,000
-574,345
-48% -$76.2M
DAWN
29
DELISTED
Day One Biopharmaceuticals
DAWN
$79.8M 0.94%
3,723,131
– –
SVRA icon
30
Savara
SVRA
$1.13B
$74.1M 0.87%
13,569,000
– –
EHAB
31
DELISTED
Enhabit
EHAB
$66.9M 0.79%
4,747,746
– –
GMAB icon
32
Genmab
GMAB
$21B
$66.1M 0.78%
+2,462,000
New +$73.8M
BIO icon
33
Bio-Rad Laboratories Class A
BIO
$10.4B
$63M 0.74%
226,070
– –
LNTH icon
34
Lantheus
LNTH
$6.56B
$62.8M 0.74%
827,999
– –
SPRY icon
35
ARS Pharmaceuticals
SPRY
$600M
$60.3M 0.71%
7,503,812
– –
STOK icon
36
Stoke Therapeutics
STOK
$2.1B
$59.4M 0.7%
1,823,500
– –
NVST icon
37
Envista
NVST
$4.41B
$56.1M 0.66%
2,210,100
-70,398
-3% -$1.83M
IDYA icon
38
IDEAYA Biosciences
IDYA
$4.03B
$51M 0.6%
1,530,008
-623,035
-29% -$20.9M
BLTE
39
Belite Bio
BLTE
$6.32B
$48.5M 0.57%
304,013
+70,200
+30% +$11.8M
BMRN icon
40
BioMarin Pharmaceuticals
BMRN
$12.6B
$48.1M 0.57%
+851,556
New +$49.7M
KYMR icon
41
Kymera Therapeutics
KYMR
$10B
$46.7M 0.55%
561,170
– –
CERT icon
42
Certara
CERT
$1.28B
$44.5M 0.53%
7,808,605
– –
BBOT
43
BridgeBio Oncology
BBOT
$736M
$43.7M 0.52%
4,885,446
– –
IRON icon
44
Disc Medicine
IRON
$3.17B
$42M 0.5%
657,000
+145,837
+29% +$10.1M
SION
45
Sionna Therapeutics
SION
$274M
$38.9M 0.46%
970,590
– –
CDNA icon
46
CareDx
CDNA
$2.71B
$38M 0.45%
2,191,000
– –
GPCR icon
47
Structure Therapeutics
GPCR
$3.51B
$37M 0.44%
767,993
– –
VCYT icon
48
Veracyte
VCYT
$3.64B
$23.4M 0.28%
726,000
– –
ALNY icon
49
Alnylam Pharmaceuticals
ALNY
$31.7B
$22.5M 0.27%
67,935
– –
EMBC icon
50
Embecta
EMBC
$282M
$22.4M 0.26%
2,534,961
-217,070
-8% -$2.26M
1
2
3 4 5

Similar funds

OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $9.53B AUM 52.96% 1-Year Est. Return
VF
Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
A
Allianz Munich, Germany $9.48B AUM 23.58% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Deerfield Management's Q1 2026 Portfolio in Review

As of Q1 2026, Deerfield Management held 160 positions worth $8.48B, up 8.3% from $7.83B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Deerfield Management withdrew a net $743M in Q1 2026, closing 78 positions and reducing 10 holdings. Its most notable exit was Phreesia, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Syndax Pharmaceuticals worth $88.3M.

  • Deerfield Management's largest Q1 2026 buy was Syndax Pharmaceuticals: 3,779,900 shares worth $88.3M.
  • Deerfield Management added most to Inspire Medical Systems in Q1 2026, an estimated $83.8M increase.
  • Deerfield Management's biggest Q1 2026 reduction was Neurocrine Biosciences, cutting an estimated $76.2M.
  • Deerfield Management fully exited Phreesia in Q1 2026, selling an estimated $33.8M.
  • Deerfield Management's ten largest holdings make up 51% of its $8.48B portfolio in Q1 2026.
  • Deerfield Management opened 9 new positions and closed 78 in Q1 2026.
  • Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $8.48B.

Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.